Meta Information

ID:aliskiren

Name:Aliskiren

Schema Version:1.5

Alternate Names

• Tekturna
• Rasilez

Active Compound

aliskiren

Intervention Type

therapeutic_agent

Delivery

Route:

oral

Scope:

• systemic

Regulatory Status

• us:rx_drug
• eu:rx_drug

Indication

Focus:

disease_treatment

Description:

Treatment of hypertension (high blood pressure) by directly inhibiting the enzyme renin.

Typical Protocol

• The standard starting dose is 150 mg taken orally once per day.
• The dose may be increased to 300 mg once per day for additional blood pressure control.

Expected Cost Mean

Low Cost:

40

High Cost:

80

Cost Type:

monthly

Description:

Monthly cost for generic Aliskiren, often covered by prescription drug insurance plans.

Summary

Aliskiren is a direct renin inhibitor, blocking the first and rate-limiting step of the renin-angiotensin-aldosterone system (RAAS). This action prevents the conversion of angiotensinogen to angiotensin I, leading to decreased levels of angiotensin II, vasodilation, and ultimately, lower blood pressure. While RAAS modulation is a key area of aging research, Aliskiren is used clinically for hypertension and has not demonstrated unique healthspan benefits beyond blood pressure control.

Purpose

A direct renin inhibitor used to treat high blood pressure.

Card Summary

A prescription oral medication that treats high blood pressure by directly inhibiting renin, the first step in the RAAS pathway.

Drug Class

direct_renin_inhibitors

Drugs In Class

Empty Array

Impact

Score:

2.5

Justification:

No evidence for healthspan benefits beyond its primary effect on blood pressure.

Evidence

Grade:

A

Score:

9

Justification:

Multiple large-scale human RCTs confirm its efficacy for treating hypertension.

Safety

Score:

5.5

Justification:

Prescription drug with risks of hyperkalemia, hypotension, and severe fetal toxicity.

Flags

• Black box warning: Can cause fetal injury and death; discontinue if pregnancy is detected.
• Should not be combined with ACE inhibitors or ARBs in patients with diabetes due to increased risk of adverse outcomes.
• Risk of hyperkalemia (high potassium), especially when combined with other RAAS inhibitors or in patients with renal impairment.
• May cause severe allergic reactions, including angioedema.
• Common side effects include diarrhea, cough, dizziness, and headache.

Verdict

A targeted hypertension drug with no proven unique healthspan benefits.

Created

2026-04-30T01:27:38.468293Z

Ai Model

Gemini 2.5 Pro (High)

Non Healthspan

True